The FDA on January 9, 2020 approved AYVAKIT® for adults with unresectable or metastatic GastroIntestinal Stromal Tumor (GIST) harboring a Platelet-Derived Growth Factor Receptor Alpha (PDGFRA) exon 18 mutation, including D842V mutations. AYVAKIT® is a product of Blueprint Medicines Corporation.
Other Pages – Bottom Ad
Advertisement
Subscribe
